Committed to changing this paradigm, Dr. Dinetz employs preventive and restorative Functional Medicine. As an early adopter of Clinical Genomics and precision medicine, he utilizes advanced biomarkers to identify and correct imbalances, extending healthspan and reversing disease trajectories that conventional medicine accepts as inevitable.

His innovative approach has led to numerous publications in peer-reviewed medical journals and popular magazines, helping physicians understand that preventing and reversing disease is both possible and practical. His expertise has earned him invitations to speak at national and international medical conferences, promoting advanced methodologies and aiding physicians in transforming medicine for the better.

Dr. Dinetz serves on the advisory boards of the Age Management Medical Group (AMMG), Forbes Health, and the Institute for Regenerative and Cellular Medicine. He has contributed to prominent publications including Psychology Today and TIME Magazine, with a focus on empowering individuals to embrace a proactive approach to health. He is a Voluntary Assistant Professor in the Department of Family Medicine at the University of Miami Miller School of Medicine, and is the founder of Timeless Health in Miami, FL.

He completed medical training at USC and residency at Stanford University and later became a Clinical Fellow in regenerative medicine at UC Irvine.

As founder of Systomic Health and leader at SelfDecode, he has pioneered genomic technologies used by biotechnology companies and global health platforms.

His work focuses on translating advanced genomic science into scalable healthcare solutions worldwide.

As COO and CFO of SelfDecode he built a B2B division generating over $100M in contracts and helped expand the company's genomics platform worldwide.

Previously he served as COO of R Systems Inc., scaling operations dramatically and leading the company through a successful IPO.

Earlier leadership roles at AT&T involved managing business units with more than $150M in annual revenue.

She has held senior medical affairs roles at Edwards Lifesciences, Daiichi Sankyo, Kite Pharma, Teva Pharmaceuticals, and Sandoz Pharmaceuticals — leading initiatives spanning KOL engagement, advisory boards, evidence generation planning, Investigator Sponsored Trials, Clinical Evidence Plans, and regulatory-aligned scientific communications across global portfolios.

Dr. Özcan holds an MD from Ondokuz Mayıs University and an MBA from DeVry University, with continuing education in Immunology from Harvard Medical School. She brings a unique blend of clinical training, business acumen, and regulatory insight — enabling her to translate complex science into actionable strategy across the life sciences ecosystem. Fluent in English and Turkish, she is culturally agile across US and global teams.